Open Access 01-12-2023 | Chronic Myeloid Leukemia | Correction
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Published in: Journal of Hematology & Oncology | Issue 1/2023
Login to get access